165 related articles for article (PubMed ID: 10823245)
1. Immunoglobulin light chains, glycosaminoglycans, and amyloid.
Stevens FJ; Kisilevsky R
Cell Mol Life Sci; 2000 Mar; 57(3):441-9. PubMed ID: 10823245
[TBL] [Abstract][Full Text] [Related]
2. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of amyloid proteins.
Benson MD; Kluve-Beckerman B; Liepnieks JJ; Murrell JR; Hanes D; Uemichi T
Ciba Found Symp; 1996; 199():104-13; discussion 113-8. PubMed ID: 8915606
[TBL] [Abstract][Full Text] [Related]
4. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
5. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.
Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V
J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
7. Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction.
Martin DJ; Ramirez-Alvarado M
Biophys Chem; 2011 Sep; 158(1):81-9. PubMed ID: 21640469
[TBL] [Abstract][Full Text] [Related]
8. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
10. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.
McLaughlin RW; De Stigter JK; Sikkink LA; Baden EM; Ramirez-Alvarado M
Protein Sci; 2006 Jul; 15(7):1710-22. PubMed ID: 16751605
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis.
Fujimoto N; Yajima M; Ohnishi Y; Tajima S; Ishibashi A; Hata Y; Enomoto U; Konohana I; Wachi H; Seyama Y
J Invest Dermatol; 2002 Mar; 118(3):479-84. PubMed ID: 11874487
[TBL] [Abstract][Full Text] [Related]
12. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of beta2 microglobulin and lambda light chain in amyloid fibrils of dialysis-unrelated plasma cell dyscrasia-associated systemic amyloidosis.
Fujimoto N; Wada N; Akiyama M; Tajima S; Ishibashi A; Miyakawa S
Br J Dermatol; 2002 Sep; 147(3):549-53. PubMed ID: 12207599
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of protein AA and immunoglobulin light-chain fragments in amyloid fibrils.
Westermark P; Natvig JB; Anders RF; Sletten K; Husby G
Scand J Immunol; 1976; 5(1-2):31-6. PubMed ID: 57640
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of the amyloidogenic kappa Bence Jones protein (FUR).
Odani S; Komori Y; Gejyo F
Amyloid; 1999 Jun; 6(2):77-88. PubMed ID: 10439113
[TBL] [Abstract][Full Text] [Related]
16. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts.
Martin EB; Williams A; Heidel E; Macy S; Kennel SJ; Wall JS
Biochem Biophys Res Commun; 2013 Jun; 436(1):85-9. PubMed ID: 23707811
[TBL] [Abstract][Full Text] [Related]
17. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
18. Specific glycosaminoglycans promote unseeded amyloid formation from beta2-microglobulin under physiological conditions.
Borysik AJ; Morten IJ; Radford SE; Hewitt EW
Kidney Int; 2007 Jul; 72(2):174-81. PubMed ID: 17495865
[TBL] [Abstract][Full Text] [Related]
19. Methods to study the structure of misfolded protein states in systemic amyloidosis.
Fändrich M; Schmidt M
Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
